Thus, understanding the ubiquitin-proteasome system of ERα protein, including numerous E3 ubiquitin ligases, coupled with modulating ERα protein stability could be a promising strategy for breast cancer therapeutics, especially for endocrine resistant patients. The gene discussed is ESR1; the disease is breast carcinoma.